Novel endotypes in heart failure: effects on guideline-directed medical therapy
- 13 December 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (48) , 4269-4276
Abstract
We sought to determine subtypes of patients with heart failure (HF) with a distinct clinical profile and treatment response, using a wide range of biomarkers from various pathophysiological domains. We performed unsupervised cluster analysis using 92 established cardiovascular biomarkers to identify mutually exclusive subgroups (endotypes) of 1802 patients with HF and reduced ejection fraction (HFrEF) from the BIOSTAT-CHF project. We validated our findings in an independent cohort of 813 patients. Based on their biomarker profile, six endotypes were identified. Patients with endotype 1 were youngest, less symptomatic, had the lowest N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and lowest risk for all-cause mortality or hospitalization for HF. Patients with endotype 4 had more severe symptoms and signs of HF, higher NT-proBNP levels and were at highest risk for all-cause mortality or hospitalization for HF [hazard ratio (HR) 1.4; 95% confidence interval (CI) 1.1-1.8]. Patients with endotypes 2, 3, and 5 were better uptitrated to target doses of beta-blockers (P < 0.02 for all). In contrast to other endotypes, patients with endotype 5 derived no potential survival benefit from uptitration of angiotensin-converting enzyme-inhibitor/angiotensin-II receptor blocker and beta-blockers (Pinteraction <0.001). Patients with endotype 2 (HR 1.29; 95% CI 1.10-1.42) experienced possible harm from uptitration of beta-blockers in contrast to patients with endotype 4 and 6 that experienced benefit (Pinteraction for all <0.001). Results were strikingly similar in the independent validation cohort. Using unsupervised cluster analysis, solely based on biomarker profiles, six distinct endotypes were identified with remarkable differences in characteristics, clinical outcome, and response to uptitration of guideline directed medical therapy.Keywords
Funding Information
- European Commission (FP7-242209-BIOSTAT-CHF, EudraCT 2010-020808-29)
This publication has 21 references indexed in Scilit:
- Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European studyEuropean Heart Journal, 2017
- A Systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: Rationale, Design, and Baseline Characteristics of BIOSTAT-CHFEuropean Journal of Heart Failure, 2016
- Phenomapping for Novel Classification of Heart Failure With Preserved Ejection FractionCirculation, 2015
- Clinical Implications of Chronic Heart Failure Phenotypes Defined by Cluster AnalysisJACC, 2014
- The Heterogeneity of Heart FailureJACC, 2014
- Phenotypic and pathophysiological heterogeneity in heart failure with preserved ejection fractionEuropean Heart Journal, 2012
- Independent Principal Component Analysis for biologically meaningful dimension reduction of large biological data setsBMC Bioinformatics, 2012
- Epidemiology and Clinical Course of Heart Failure with Preserved Ejection FractionEuropean Journal of Heart Failure, 2011
- The chitinase and chitinase-like proteins: a review of genetic and functional studies in asthma and immune-mediated diseasesCurrent Opinion in Allergy and Clinical Immunology, 2009
- A toolbox for -centroids cluster analysisComputational Statistics & Data Analysis, 2006